College of Physicians and Surgeons Columbia−Presbyterian Medical Center, New York, New York 10032, USA
Even though diagnosis of prostate cancer can be made earlier than in the past, prognosis is still difficult. The discovery of new metastatic markers should aid in treatment design.
REFERENCES
Boring, C.C., Squires, T.S. & Tong, T. Cancer statistics. CA45, 8−31 (1995). | PubMed |
Partin, A.W. et al. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years. Urol. Clin. North Am.20, 713−725 (1993). | PubMed | ISI | ChemPort |
Stamey, T.A. et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy patients. J. Urol.141, 1076−1083 (1989). | PubMed | ISI | ChemPort |
Partin, A.W. et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology45, 831−837 (1995). | Article | PubMed | ISI | ChemPort |
Thompson, T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells2, 345−354 (1990). | PubMed | ISI | ChemPort |
Fishman, J.R., Gumerlock, P.H., Meyers, F.J. & De Vere White, R.W. Quantitation of NM23 expression in human prostate cancer tissues. J. Urol.152, 202−207 (1994). | PubMed | ISI | ChemPort |
Dong, J.T. et al. KAI1, a metastases suppressor gene for prostate cancer on human chromosome 11p11.2. Science268, 884−886 (1995). | PubMed | ISI | ChemPort |
